Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lun K. Tsou is active.

Publication


Featured researches published by Lun K. Tsou.


Proceedings of the National Academy of Sciences of the United States of America | 2010

Tandem fluorescence imaging of dynamic S-acylation and protein turnover

Mingzi M. Zhang; Lun K. Tsou; Guillaume Charron; Anuradha S. Raghavan; Howard C. Hang

The functional significance and regulation of reversible S-acylation on diverse proteins remain unclear because of limited methods for efficient quantitative analysis of palmitate turnover. Here, we describe a tandem labeling and detection method to simultaneously monitor dynamic S-palmitoylation and protein turnover. By combining S-acylation and cotranslational fatty acid chemical reporters with orthogonal clickable fluorophores, dual pulse-chase analysis of Lck revealed accelerated palmitate cycling upon T-cell activation. Subsequent pharmacological perturbation of Lck palmitate turnover suggests yet uncharacterized serine hydrolases contribute to dynamic S-acylation in cells. In addition to dually fatty-acylated proteins, this tandem fluorescence imaging method can be generalized to other S-acylated proteins using azidohomoalanine as a methonine surrogate. The sensitivity and efficiency of this approach should facilitate the functional characterization of cellular factors and drugs that modulate protein S-acylation. Furthermore, diverse protein modifications could be analyzed with this tandem imaging method using other chemical reporters to investigate dynamic regulation of protein function.


Bioorganic & Medicinal Chemistry Letters | 2010

Discovery of a synthetic dual inhibitor of HIV and HCV infection based on a tetrabutoxy-calix[4]arene scaffold.

Lun K. Tsou; Ginger E. Dutschman; Elizabeth A. Gullen; Maria Telpoukhovskaia; Yung-Chi Cheng; Andrew D. Hamilton

A potential anti-HIV and HCV drug candidate is highly desirable as coinfection has become a worldwide public health challenge. A potent compound based on a tetrabutoxy-calix[4]arene scaffold that possesses dual inhibition for both HIV and HCV is described. Structural activity relationship studies demonstrate the effects of lower-rim alkylation in maintaining cone conformation and upper-rim interacting head groups on the calix[4]arene play key roles for its potent dual antiviral activities.


Journal of the American Chemical Society | 2016

Antibacterial Flavonoids from Medicinal Plants Covalently Inactivate Type III Protein Secretion Substrates

Lun K. Tsou; Maria Lara-Tejero; Jordan RoseFigura; Zhenrun J. Zhang; Yen-Chih Wang; Jacob S. Yount; Matthew Lefebre; Paul D. Dossa; Junya Kato; Fulan Guan; Wing Lam; Yung-Chi Cheng; Jorge E. Galán; Howard C. Hang

Traditional Chinese Medicines (TCMs) have been historically used to treat bacterial infections. However, the molecules responsible for these anti-infective properties and their potential mechanisms of action have remained elusive. Using a high-throughput assay for type III protein secretion in Salmonella enterica serovar Typhimurium, we discovered that several TCMs can attenuate this key virulence pathway without affecting bacterial growth. Among the active TCMs, we discovered that baicalein, a specific flavonoid from Scutellaria baicalensis, targets S. Typhimurium pathogenicity island-1 (SPI-1) type III secretion system (T3SS) effectors and translocases to inhibit bacterial invasion of epithelial cells. Structurally related flavonoids present in other TCMs, such as quercetin, also inactivated the SPI-1 T3SS and attenuated S. Typhimurium invasion. Our results demonstrate that specific plant metabolites from TCMs can directly interfere with key bacterial virulence pathways and reveal a previously unappreciated mechanism of action for anti-infective medicinal plants.


Antimicrobial Agents and Chemotherapy | 2010

A Novel Class of meso-Tetrakis-Porphyrin Derivatives Exhibits Potent Activities against Hepatitis C Virus Genotype 1b Replicons In Vitro

Yao Cheng; Lun K. Tsou; Jianfeng Cai; Toshihiro Aya; Ginger E. Dutschman; Elizabeth A. Gullen; Susan P. Grill; Annie Pei Chun Chen; Brett D. Lindenbach; Andrew D. Hamilton; Yung-Chi Cheng

ABSTRACT Recent years have seen the rapid advancement of new therapeutic agents against hepatitis C virus (HCV) in response to the need for treatment that is unmet by interferon (IFN)-based therapies. Most antiviral drugs discovered to date are small molecules that modulate viral enzyme activities. In the search for highly selective protein-binding molecules capable of disrupting the viral life cycle, we have identified a class of anionic tetraphenylporphyrins as potent and specific inhibitors of the HCV replicons. Based on the structure-activity relationship studies reported herein, meso-tetrakis-(3,5-dicarboxy-4,4′-biphenyl) porphyrin was found to be the most potent inhibitor of HCV genotype 1b (Con1) replicon systems but was less effective against the genotype 2a (JFH-1) replicon. This compound induced a reduction of viral RNA and protein levels when acting in the low nanomolar range. Moreover, the compound could suppress replicon rebound in drug-treated cells and exhibited additive to synergistic effects when combined with protease inhibitor BILN 2061 or with IFN-α-2a. Our results demonstrate the potential use of tetracarboxyphenylporphyrins as potent anti-HCV agents.


ChemBioChem | 2009

Surface Binding Inhibitors of the SCF–KIT Protein–Protein Interaction

David Margulies; Yarden Opatowsky; Steven Fletcher; Ishu Saraogi; Lun K. Tsou; Sourav Saha; Irit Lax; Joseph Schlessinger; Andrew D. Hamilton

KIT is a receptor tyrosine kinase (RTK), the interaction of which with its ligand, stem cell factor (SCF), is essential for growth and differentiation of various cells.[1] SCF binding promotes KIT dimerization,[2] transphosphorylation, and activation of downstream cell signaling pathways essential for cell proliferation, differentiation, and survival. Gain-of-function mutations in KIT have been identified in human cancers such as gastrointestinal stromal tumors (GIST).[3,4] It was also demonstrated that autocrine or paracrine mechanisms mediated by aberrant expression of SCF and/or KIT might also lead to oncogenesis.[5–7] Because most cases of GIST are driven by oncogenic KIT mutations resulting in enhanced tyrosine kinase activity, inhibitors of the tyrosine kinase[8] activity of KIT, such as Gleevec® (imatinib mesylate) and Sutent® (sunitinib), have been successfully applied for the treatment of GIST patients.


MedChemComm | 2013

Small molecules aimed at type III secretion systems to inhibit bacterial virulence

Lun K. Tsou; Paul D. Dossa; Howard C. Hang

The development of new anti-bacterial compounds presents a major challenge to modern medicine as bacterial strains resistant to traditional antibiotics are constantly emerging. Type III secretion systems (T3SSs) are essential for virulence mechanisms of many Gram-negative bacterial pathogens and have therefore emerged as an attractive target for small molecule anti-virulence therapeutics. This has led to several high-throughput screens in search for specific chemicals that inhibit the secretion and translocation of bacterial effector proteins. Several classes of small molecules have now been identified from these screens and this review focuses on their discovery and discusses their potential mechanisms of action and prospects for clinical development.


Organic and Biomolecular Chemistry | 2009

Clickable fluorescent dyes for multimodal bioorthogonal imaging

Lun K. Tsou; Mingzi M. Zhang; Howard C. Hang

Bioorthogonal ligation with functionalized fluorescent dyes enables visualization of nuclei acids, proteins and metabolites in biological systems. Bright and modular azide- and alkyne-functionalized dyes are therefore needed to expand the fluorescence imaging capabilities of bioorthogonal ligation methods. We describe the concise synthesis of clickable fluorescent dyes based on 2-dicyanomethylene-3-cyano-2,5-dihydrofuran fluorophores and demonstrate their utility for multicolor imaging of azide- and alkyne-modified proteins as well as FRET studies.


Journal of Medicinal Chemistry | 2015

Function-oriented development of CXCR4 antagonists as selective human immunodeficiency virus (HIV)-1 entry inhibitors.

Chien-Huang Wu; Chuan-Jen Wang; Chun-Ping Chang; Yung-Chi Cheng; Jen-Shin Song; Jiing-Jyh Jan; Ming-Chen Chou; Yi-Yu Ke; Jing Ma; Ying-Chieh Wong; Tsung-Chih Hsieh; Yun Chen Tien; Elizabeth A. Gullen; Chen-Fu Lo; Chia-Yi Cheng; Yu-Wei Liu; Amit A. Sadani; Chia-Hua Tsai; Hsin-Pang Hsieh; Lun K. Tsou; Kak-Shan Shia

Motivated by the pivotal role of CXCR4 as an HIV entry co-receptor, we herein report a de novo hit-to-lead effort on the identification of subnanomolar purine-based CXCR4 antagonists against HIV-1 infection. Compound 24, with an EC50 of 0.5 nM against HIV-1 entry into host cells and an IC50 of 16.4 nM for inhibition of radioligand stromal-derived factor-1α (SDF-1α) binding to CXCR4, was also found to be highly selective against closely related chemokine receptors. We rationalized that compound 24 complementarily interacted with the critical CXCR4 residues that are essential for binding to HIV-1 gp120 V3 loop and subsequent viral entry. Compound 24 showed a 130-fold increase in anti-HIV activity compared to that of the marketed CXCR4 antagonist, AMD3100 (Plerixafor), whereas both compounds exhibited similar potency in mobilization of CXCR4(+)/CD34(+) stem cells at a high dose. Our study offers insight into the design of anti-HIV therapeutics devoid of major interference with SDF-1α function.


Journal of the American Chemical Society | 2010

Visible Fluorescence Detection of Type III Protein Secretion from Bacterial Pathogens

Jacob S. Yount; Lun K. Tsou; Paul D. Dossa; Amy L. Kullas; Adrianus W. M. van der Velden; Howard C. Hang

Type III protein secretion is essential for many gram-negative bacterial infections of host cells and an attractive target for new antibacterial drugs. Here, we describe a bacterial protein effector-carboxypeptidase G2 (CPG2) reporter system for fluorescence and visible detection of type III protein secretion in Salmonella typhimurium. This system provides a general method for measuring protein expression and secretion as well as a high-throughput and quantitative assay for analyzing type III protein secretion inhibitors.


Bioorganic & Medicinal Chemistry Letters | 2012

Blocking HIV-1 entry by a gp120 surface binding inhibitor.

Lun K. Tsou; Chin Ho Chen; Ginger E. Dutschman; Yung-Chi Cheng; Andrew D. Hamilton

We report the mode of action of a proteomimetic compound that binds to the exterior surface of gp120 and blocks HIV-1 entry into cells. Using a one cycle time-of-addition study and antibody competition binding studies, we have determined that the compound blocks HIV-1 entry through modulation of key protein-protein interactions mediated by gp120. The compound exhibits anti-HIV-1 replication activities against several pseudotype viruses derived from primary isolates and the resistant strains isolated from existing drug candidates with equal potency. Together, these data provide evidence that the proteomimetic compound represents a novel class of HIV-1 viral entry inhibitor that functions through protein surface recognition in analogy to an antibody.

Collaboration


Dive into the Lun K. Tsou's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Chien-Huang Wu

National Health Research Institutes

View shared research outputs
Top Co-Authors

Avatar

Kak-Shan Shia

National Health Research Institutes

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yu-Wei Liu

National Health Research Institutes

View shared research outputs
Top Co-Authors

Avatar

Chiung-Tong Chen

National Health Research Institutes

View shared research outputs
Top Co-Authors

Avatar

Chun-Ping Chang

National Health Research Institutes

View shared research outputs
Top Co-Authors

Avatar

Jen-Shin Song

National Health Research Institutes

View shared research outputs
Researchain Logo
Decentralizing Knowledge